FDA 483 - Omega Laboratories Ltd. - January 17, 2024

An FDA inspection of Omega Laboratories Ltd. in Montreal revealed significant deficiencies in aseptic processing controls. Observations included equipment design flaws that compromised sterility during vial filling and a lack of proper disinfection after operator contact during critical setup and interventions. These issues raise concerns about the safety and purity of sterile drug products manufactured at the facility.